// App-Quantinova.ai

DOP38 : A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease

Researchers

Presenter

  • B Verstockt

Principal Investigators

  • S Verstockt

  • P Sudahakar

  • J Dehairs

  • H Blevi

  • G Van Assche

  • S Vermeire

  • M Ferrante

Medical Centers

  • Department of Gastroenterology , Univ. Hospitals Leuven, Leuven, Belgium

  • KU Leuven, Department of Chronic Diseases- Metabolism and Ageing- Translational Research Center for Gastrointestinal Disorders TARGID, Leuven, Belgium

  • Department of Human Genetics, Laboratory for Complex Genetics, KU Leuven, Leuven, Belgium

  • Earlham Institute, Norwich, UK

  • Quadram Institute, Norwich, Belgium

  • Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium

Locations

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Genetic Disorder

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved